IQ MPS
IQ Microphysiological Systems Affiliate
An Affiliate of the International Consortium for Innovation and Quality in Drug Development
NEW | Scientific Engagement Series for CIVM Developers and Providers
This scientific engagement series provides a forum for developers and providers of complex in vitro models (CIVMs) to present technologies and receive direct feedback from IQ MPS member companies on qualification, reproducibility, and application in drug development.
About
In support of our mission to foster a collaborative scientific ecosystem, the IQ MPS Affiliate seeks to promote engagement between developers and/or providers of complex in vitro models (CIVMs) and pharmaceutical end users. To this end, we have established a new forum through which CIVM providers may apply to participate in scientific engagement sessions with IQ MPS member companies. These sessions are designed to facilitate discussion of established or emerging CIVMs, with particular focus on qualification, reproducibility, context of use, and applications across drug discovery and development. CIVM platforms within the scope of this call include, but are not limited to, micropatterned co-cultures; three-dimensional (3D) microtissues such as spheroids and organoids; 3D-bioprinted tissues; and microphysiological systems (MPS) that incorporate multicellular environments, three-dimensional architectures, and physiologically relevant cues.
The scientific engagement will take the form of an interactive meeting with IQ MPS member representatives, the first of these sessions will be at the MPS World Summit. Participating providers will briefly present their technology, followed by a live, open discussion with IQ MPS affiliate attendees. Respondents will have the opportunity to propose specific topics for discussion in advance. During the session, model providers are encouraged to address technical considerations, study designs, and current challenges associated with their CIVM platforms, with the goal of obtaining direct feedback from pharmaceutical end users.
Technical Requirements
This call is open to developers of CIVM across both commercial and academic settings, as well as outsourced research partners (i.e. CROs) that provide these platforms for pharmaceutical applications. Proposals are welcome at all stages of model development from ideation and proof-of-concept through to validated, deployed, and marketed products.
The information submitted via the below application will be reviewed by IQ MPS Affiliate members to inform the selection of respondents to participate in a scientific engagement session. The IQ MPS Affiliate may select respondent(s) based solely upon responses given below or may choose to request clarification on information provided by respondent(s) or request additional technical details. The contents and information provided in this open call inquiry are meant to provide and gather general information to and from interested parties.
When responding to this inquiry, please note the following:
Do not include pricing or market-related information in your responses.
Engagement feedback will remain technical and non-binding; no written feedback will be provided for the following sessions.
Selection to engage with the Consortium based on responses to this inquiry does not constitute endorsement by the Consortium. The Consortium will not be seen to endorse a Respondent, idea or topic simply because they are chosen to engage with the IQ MPS Affiliate. Any questions or feedback given by IQ MPS or any Member representatives do not constitute endorsement.
This inquiry is not an offer or contract on behalf of the IQ Consortium or the respondents.
The IQ MPS Affiliate is not obligated to respond to or contract with any Respondents to this inquiry.
Anything submitted in response to this inquiry will become property of the IQ Consortium.
Respondents will not be compensated or reimbursed for any costs incurred as part of the inquiry or Scientific Engagement process.
The IQ MPS Affiliate reserves the right to accept or reject any or all responses for any reason.
Disclaimer: Please note that this is not a solicitation for proposals or funding opportunities.
Application Process
Applications will be accepted on a rolling basis and reviewed quarterly Q2 2026 through Q2 2028.
Logistics and availability permitting, the first Engagement meeting in this series may be held in person at the MPS World Summit (May 26–29, 2026, Washington, D.C.). To be considered for participation in this in-person session, the “interest to engage” form must be submitted by May 5, 2026.